Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...
Ruxolitinib cream demonstrated favorable safety and efficacy in pediatric atopic dermatitis, highlighting JAK inhibitors' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback